openPR Logo
Press release

Lawsuit filed for Investors in shares of Evolus, Inc. (NASDAQ: EOLS)

10-22-2020 02:59 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Evolus, Inc. (NASDAQ: EOLS) shares over alleged securities laws violations.

A lawsuit was filed on behalf of investors in Evolus, Inc. (NASDAQ: EOLS) shares over alleged securities laws violations.

An investor, who purchased shares of Evolus, Inc. (NASDAQ: EOLS), filed a lawsuit over alleged violations of Federal Securities Laws by Evolus, Inc.

Investors who purchased shares of Evolus, Inc. (NASDAQ: EOLS) have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2020. NASDAQ: EOLS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

An International Trade Commission judge issued a preliminary ruling on trade secrets action involving Evolus, Inc. on July 6, 2020. The non-binding decision sided with Allergan and its partner Medytox in finding that the Company and its South Korean partner firm Daewoong developed its Jeuveau product using stolen trade secrets. The judge recommended a 10-year ban on the importation of Jeuveau into the United States.

Shares of Evolus, Inc. (NASDAQ: EOLS) declined from $29.40 per share in April 2019, to as low as $3.00 per share on July 9, 2020.

The plaintiff claims that between February 1, 2019 to July 6, 2020, Evolus made false and misleading statements to the public and failed to disclose that the real source of botulinum toxin bacterial strain as well as the manufacturing processes used to develop Jeuveau™ originated with and were misappropriated from Medytox, that sufficient evidentiary support existed for the allegations that Evolus misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau™, that as a result, Evolus faced a real threat of regulatory and/or court action, prohibiting the import, marketing, and sale of Jeuveau™, that which in turn seriously threatened Evolus’ ability to commercialize Jeuveau™ in the United States and generate revenue, and that any revenues generated from the sale of Jeuveau™ were based on Evolus’ unlawful activities, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox.

Those who purchased shares of Evolus, Inc. (NASDAQ: EOLS) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Evolus, Inc. (NASDAQ: EOLS) here

News-ID: 2167555 • Views:

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) over possible Violations of Securities Laws
Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NA …
An investigation was announced for investors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) shares over potential securities laws violations by Lifecore Biomedical, Inc. Investors who purchased shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Lifecore Biomedical, Inc. regarding its business, its prospects and
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: DBI) over potential Wrongdoing by certain directors
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: D …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Designer Brands Inc. Investors who purchased shares of Designer Brands Inc. (NYSE: DBI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Designer Brands Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. Columbus,
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. …
An investor, who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ), filed a lawsuit over alleged violations of Federal Securities Laws by Innoviz Technologies Ltd. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) have certain options and for certain investors are short and strict deadlines running. Deadline: May 14, 2024. NASDAQ: INVZ investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NASDAQ: IRBT)
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NA …
An investor, who purchased shares of iRobot Corporation (NASDAQ: IRBT), filed a lawsuit over alleged violations of Federal Securities Laws by iRobot Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of iRobot Corporation (NASDAQ: IRBT) have certain options and for certain investors are short and strict deadlines running. Deadline: May 7, 2024. NASDAQ: IRBT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)

All 5 Releases


More Releases for Evolus

Aesthetic Dermatology Business Opportunities and Forecast to 2029: AbbVie Inc. ( …
Data Bridge Market Research analyses that the global aesthetic dermatology market will grow at a CAGR of 10.2% during the forecast period of 2022 to 2029. Aesthetic Dermatology Market Report offers intelligent records on enterprise methodologies and subjective and quantitative research of the worldwide market. The report additionally asks that the results of the show off start to decide the possibilities that suggest the desires of the clients. guarantees qualified and
Online Diagram Editor Market Is Booming So Rapidly | Top Players - Visio, Gliffy …
Stay up-to-date and exploit latest trends of Online Diagram Editor Market with latest edition released by AMA. A Latest intelligence report published by AMA Research with title "Online Diagram Editor Market Outlook to 2027.A detailed study accumulated to offer Latest insights about acute features of the Global Online Diagram Editor market. This report provides a detailed overview of key factors in the Online Diagram Editor Market and factors such as driver,
Online Diagram Editor Market Pegged for Robust Expansion by 2027 | Evolus, MyDra …
This Online Diagram Editor market report provides a thorough insight of the market, allowing key players to keep informed and keep their competitive advantage. It focuses on present trends by forecasting future trends, market size, and market features. Such meticulous Market Analysis creates a comprehensive picture of market policies and supports industries in making larger earnings than before. The greatest way to gain insight into the current market situation and
Investigation announced for Long-Term Investors in shares of Evolus, Inc. (NASDA …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Evolus, Inc. Investors who are current long term investors in Evolus, Inc. (NASDAQ: EOLS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: EOLS stocks follows a lawsuit filed against Evolus, Inc. over alleged
Deadline on Dec. 15th coming up in Lawsuit for Investors in shares of Evolus, In …
A deadline is coming up on December 15, 2020 in the lawsuit filed for certain investors of Evolus, Inc. (NASDAQ: EOLS) over alleged securities laws violations by Evolus, Inc. Investors who purchased shares of Evolus, Inc. (NASDAQ: EOLS) have certain options and there are strict and short deadlines running. Deadline: December 15, 2020. NASDAQ: EOLS stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the
Investigation announced for Investors in shares of Evolus, Inc. (NASDAQ: EOLS)
An investigation was announced concerning potential securities laws violations by Evolus, Inc. in connection with certain financial statements. Investors who purchased shares of Evolus, Inc. (NASDAQ: EOLS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Evolus, Inc. regarding its business, its prospects and its operations were materially false and